NCT04165070 2026-03-16
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
33 trialsNCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT07281976 2026-02-12
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT04396821 2025-12-17
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT07280377 2025-12-12
GOBLET
Oncolytics Biotech
Phase 1/2 Recruiting
NCT05669482 2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT06953323 2025-08-13
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06592664 2025-06-06
FORTIFIDE
Lisata Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
NCT01834235 2025-05-07
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
Phase 1/2 Terminated
NCT05827796 2025-04-30
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT05586516 2025-03-20
A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Active not recruiting
NCT05431270 2025-01-31
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT03950570 2024-12-31
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Orinove, Inc.
Phase 1/2 Completed
NCT03189914 2023-12-06
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Processa Pharmaceuticals
Phase 1/2 Completed
NCT01325441 2023-11-15
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT04983407 2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
Aravive, Inc.
Phase 1/2 Terminated
NCT03138889 2023-03-10
PROPEL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02210559 2023-03-02
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio
Phase 1/2 Completed
NCT01647828 2023-02-15
ALPINE
Mereo BioPharma
Phase 1/2 Completed
NCT02762981 2022-12-06
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
Phase 1/2 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT04210037 2022-07-12
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT04460066 2022-05-04
A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.
Lee's Pharmaceutical Limited
Phase 1/2 Unknown
NCT02077881 2020-05-28
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01962103 2019-12-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 1/2 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT00398086 2019-11-22
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Celgene
Phase 1/2 Completed
NCT01858883 2019-07-18
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT01971281 2017-09-13
Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
NovoCure Ltd.
Phase 1/2 Unknown
NCT00073723 2016-12-15
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Celgene Corporation
Phase 1/2 Completed